The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination• Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health• Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02•

Category: Editor’s Choice

Microbiome ‘editing’ for infectious disease and more: An overview of bacteriophage drug development
Editor's Choice

Microbiome ‘editing’ for infectious disease and more: An overview of bacteriophage drug development

DEC 1, 2021
Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives
Editor's Choice

Enabling the Commercialization of Microbiome Live Biotherapeutic Products with Fit-for-Purpose Cryopreservatives

NOV 23, 2021
Engineering the Microbiome to Treat Skin Diseases
Biotech Showcase

Engineering the Microbiome to Treat Skin Diseases

NOV 16, 2021
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection
Editor's Choice

Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection

SEP 30, 2021
Microbes turn back the clock as research discovers their potential to reverse aging in the brain
Editor's Choice

Microbes turn back the clock as research discovers their potential to reverse aging in the brain

AUG 31, 2021
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
Editor's Choice

Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement

JUL 2, 2021
Ferring and Rebiotix Present Landmark Phase 3 Data
Clinical & Manufacturing

Ferring and Rebiotix Present Landmark Phase 3 Data

MAY 24, 2021
The surprising evolutionary history of our oral bacteria
Editor's Choice

The surprising evolutionary history of our oral bacteria

MAY 12, 2021
Fecal transplant turns cancer immunotherapy non-responders into responders
Editor's Choice

Fecal transplant turns cancer immunotherapy non-responders into responders

FEB 10, 2021
Why microbiota samples should be collected in all clinical trials?
Clinical & Manufacturing

Why microbiota samples should be collected in all clinical trials?

JAN 26, 2021
Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19
Editor's Choice

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

JAN 20, 2021